Scientific deep-dive
Handgrip Strength and Sarcopenic Obesity
Over twelve months on semaglutide, handgrip strength rose 4.5 kg and sarcopenic obesity fell from 49% to 33%, while lean mass declined early then stabilized rather than continuing down.
Almost everything written about muscle and these drugs measures mass on a scan. The SEMALEAN study measured something better: what people could do. Over twelve months on semaglutide 2.4 mg, handgrip strength improved by 4.5 kg, and the prevalence of sarcopenic obesity fell from 49% to 33%.[1]
What happened, in order
Fat mass fell 18% by month twelve. Lean mass declined by about 3 kg by month seven, then stabilized rather than continuing down.[1]
The lean-mass loss is front-loaded, and then it stops. It is not a slope that continues for as long as you take the drug.
That shape matters for the argument people are having. “These drugs eat your muscle” implies an ongoing process. What this describes is an early adjustment as body size falls, followed by a plateau. That is what you would expect if lean loss is a consequence of needing less muscle to move a smaller body.
The functional results
- Handgrip strength rose 4.5 kg by month twelve. Grip strength is a standard, hard-to-fake proxy for whole-body strength and a well-validated predictor of outcomes.
- Sarcopenic obesity fell from 49% to 33%. That is a net fall in a formal diagnosis: 22% of participants lost it by month twelve and 5% newly developed it.[1]
- Resting energy expenditure normalized to lean mass rose between months seven and twelve, meaning the remaining tissue was not becoming metabolically sluggish.
This is consistent with a smaller study we covered in muscle volume versus muscle function, where psoas volume fell 9.3% while chair-rise time and walking speed both improved slightly. Two independent studies finding mass down and function up is a more useful pattern than either alone.
Who responded differently
Three subgroup findings stand out, and one is directly practical.
- Women lost more weight and fat mass, consistent with the randomized picture in who loses more weight.
- People with type 2 diabetes, or prior GLP-1 use, showed attenuated responses. The diabetes finding is well established. The prior-use one matters for anyone switching drugs (see switching).
- People with a history of bariatric surgery showed the most pronounced changes, which is relevant to the growing group taking these drugs after weight regain following surgery.
The prior-GLP-1 finding deserves particular attention because it is rarely mentioned. If you have taken one of these drugs before, the response to the next may be smaller than the trial figures suggest, because trial populations are typically drug-naive.
Frequently Asked Questions
References
- 1.Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study Diabetes, Obesity and Metabolism. 2026. PMID: 41068996.
Compare the sellers
Related research
Muscle Volume Versus Muscle Function on a GLP-1
Psoas muscle volume fell 9.3% over 24 weeks while chair-rise time and walking speed both edged better. Mass and function moved in opposite directions in the same people, and only one of them is what anybody wants.
6 min read
GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence
A phase 2b randomized trial found once-weekly semaglutide cut abdominal visceral fat by about 30.6% over 32 weeks in people with HIV-associated lipohypertrophy, alongside a 9.3% fall in psoas muscle volume that did not cost measurable function.
6 min read
GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not
In a controlled case series of five people with chronic spinal cord injury, three on weekly semaglutide lost weight, fat mass and visceral fat over 26 weeks while the two untreated participants gained on every measure.
5 min read
Muscle Loss: Drug Versus Dieting
Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.
6 min read
Bimagrumab Plus Semaglutide: The Muscle Question
The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.
6 min read
Collagen Peptides: What the Trials Show for Skin, Joints, Bone and Muscle
Pooled trials show better skin hydration with collagen peptides, but a 2025 meta-analysis found no effect in trials not funded by companies. Knee and other osteoarthritis pain eases modestly. For muscle, collagen did less than whey or pea protein, which matters on a GLP-1.
9 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
YourEra
From $99/mo
Get started →Collective
From $59/mo + membership
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →